ライフサイエンスコーパス: amoxicillin

1 ess to core Access antibiotics, particularly amoxicillin.

2 lude intramuscular gentamicin (GEN) and oral amoxicillin.

3 t this condition may be noninferior to using amoxicillin.

4 ectrum antibiotic prescriptions, in favor of amoxicillin.

5 , 95% CI [-92.8; -32.7]) and was replaced by amoxicillin.

6 d procaine benzylpenicillin, gentamicin, and amoxicillin.

7 wed resistance to penicillin, ampicillin and amoxicillin.

8 firmatory test for skin-related reactions to amoxicillin.

9 rative inflammation to a greater extent than amoxicillin.

10 -gentamicin and 1163 infants to receive oral amoxicillin.

11 % (n = 60/95) of them were resistant against amoxicillin.

12 daily injections and the first dose of oral amoxicillin.

13 , and one case of anaphylaxis was noted with amoxicillin.

14 root planing and systemic metronidazole and amoxicillin.

15 ntibiotic challenge by a low-dose regimen of amoxicillin.

16 sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor

17 ected were randomly assigned (1:1) to either amoxicillin (1 g three times daily for 7 days) or placeb

18 e risk of treatment failure with placebo vs. amoxicillin, 1.32; 95% confidence interval [CI], 1.04 to

19 ely (relative risk of death with placebo vs. amoxicillin, 1.55; 95% CI, 1.07 to 2.24; relative risk w

20 n = 103) received pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h and clarithromycin (CLARI) 5

21 n were prescribed pantoprazole 40 mg 2x/day, amoxicillin 1000 mg 12/12 h and LVX 250 mg 12/12 h, for

22 el was exposed to metronidazole (15 mug/mL), amoxicillin (15 mug/mL), metronidazole and amoxicillin i

23 days allowing discharge of the patient with amoxicillin (2 g tid per os).

24 imethoprim-sulfamethoxazole, penicillin, and amoxicillin (22%, 8/37 each).

25 oup EA, n = 20) or without (group E, n = 20) amoxicillin (250 mg three times daily for 5 days).

26 rifabutin, 150 mg) versus active comparator (amoxicillin, 3 g, and omeprazole, 120 mg), given as 4 ca

27 RHB-105 (amoxicillin, 3 g; omeprazole, 120 mg; and rifabutin, 150

28 icrobials tested for susceptibility pattern; amoxicillin 38.7%, ciprofloxacin 25.8%, chloramphinicol

29 whom received subsequent full treatment with amoxicillin; 49 of these 55 participants (89.1%) reporte

30 lmonella Typhi, 89 (89.9%) were resistant to amoxicillin, 85 (81.0%) to chloramphenicol, and 93 (92.1

31 Among antibiotics, amoxicillin (97 cases), other penicillins (four cases),

32 igned to either 7 d of peroral metronidazole/amoxicillin AB treatment or no AB, along with standard c

33 Amoxicillin accounted for 64.8% of dental antibiotic pre

34 A 3-day course of oral amoxicillin, administered by LHWs, is an effective and s

35 with AMP, ERT, ceftaroline, ceftriaxone, or amoxicillin against DAP-R E. faecium R497 using establis

36 Amoxicillin alone or combined to clavulanic acid were th

37 ly reduced by doxycycline, azithromycin, and amoxicillin alone or in combination with metronidazole,

38 as well as Campylobacter rectus (except for amoxicillin alone).

39 rowth inhibition were detected compared with amoxicillin alone.

40 Other amoxicillin alternatives, clarithromycin and metronidazo

41 nsity score-matched adults treated with oral amoxicillin (amoxicillin cohort = 178 179 prescriptions)

42 mproved bactericidal efficacy in addition to amoxicillin, ampicillin and cefotaxime.

43 -lactam antibiotics, including penicillin-G, amoxicillin, ampicillin, and cefazolin, are protected fr

44 recorded for selected antibiotics, including amoxicillin, ampicillin, lomefloxacin, and ofloxacin.

45 Use of amoxicillin/ampicillin may lead to overgrowth of K. pneu

46 beta-lactam antibiotics ampicillin (Amp) and amoxicillin (Amx) are linked to a monofunctionalized ent

47 2-years effects of metronidazole (MTZ) plus amoxicillin (AMX) as adjuncts to scaling and root planin

48 igated for the quantitative determination of amoxicillin (AMX) as well as qualitative analysis of met

49 he adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of smokers and non-sm

50 s and is inhibited by azithromycin (AZM) and amoxicillin (AMX).

51 r test (E-test) for clarithromycin (CLR) and amoxicillin (AMX).

52 nts treated with 40 mg pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7

53 In group A, patients received 375 mg amoxicillin and 500 mg metronidazole three times per day

54 received either systemic antibiotics (375 mg amoxicillin and 500 mg metronidazole, three times daily)

55 An antibiotherapy associating intravenous amoxicillin and amoxicillin/clavulanate was administered

56 Both amoxicillin and ampicillin produce [M + H](+), [M + CH3O

57 nophen-sulfate metabolite levels in both the amoxicillin and ampicillin/neomycin treated animals.

58 ed RRs for current users of FQ compared with amoxicillin and azithromycin users were 2.40 (95% CI: 1.

59 Rate ratios (RRs) were compared to users of amoxicillin and azithromycin.

60 .7%) and 21 of 261 (8.0%) of patients in the amoxicillin and benzyl penicillin arms, respectively (ri

61 nferiority margin of risk difference between amoxicillin and benzyl penicillin groups was prespecifie

62 apy (STT) with proton pump inhibitors (PPI), amoxicillin and clarithromycin (CLA) has been the standa

63 The strongest association was with amoxicillin and clavulanate-associated DILI in persons o

64 Seven women withdrew, leaving 1715 in the amoxicillin and clavulanic acid group and 1705 in the pl

65 Significantly fewer women allocated to amoxicillin and clavulanic acid had a confirmed or suspe

66 ated to receive a single dose of intravenous amoxicillin and clavulanic acid or placebo (saline) foll

67 up reported a skin rash and two women in the amoxicillin and clavulanic acid reported other allergic

68 a course of empirical systemic antibiotics (amoxicillin and clavulanic acid, 375 mg, to be taken 3 t

69 were randomly assigned to treatment: 1719 to amoxicillin and clavulanic acid, and 1708 to placebo.

70 Oral amoxicillin and cotrimoxazole were widely available at l

71 Further, a control group without amoxicillin and extractions (group C, n = 17) was includ

72 tamicin (reference), 76 (10%) of those given amoxicillin and gentamicin (risk difference with referen

73 micin, 816 (751 per protocol) were allocated amoxicillin and gentamicin, and 817 (753 per protocol) w

74 lowing prescription of clarithromycin versus amoxicillin and in particular, the association with P-gp

75 association between recent use of ampicillin/amoxicillin and KPLA.

76 In cases with severe periodontitis (N = 24), amoxicillin and metronidazole (AM) were prescribed for 7

77 In cases with severe periodontitis (n = 24), amoxicillin and metronidazole (AM) were prescribed for 7

78 effect of the concomitant administration of amoxicillin and metronidazole adjunctive to SRP in adult

79 antimicrobial therapy using a combination of amoxicillin and metronidazole as an adjunct to SRP can e

80 Azithromycin, the combination of Amoxicillin and Metronidazole, and Amoxicillin were the

81 ival periodontal pathogens resistant to both amoxicillin and metronidazole, which were mostly either

82 nd root planing, and a 7-day prescription of amoxicillin and metronidazole.

83 effects were displayed by the combination of amoxicillin and metronidazole.

84 g/L, with a post hoc combination of data for amoxicillin and metronidazole.

85 and ZNF300 predicted skin test positivity to amoxicillin and other penicillins but not to cephalospor

86 15-22) for levofloxacin, 3% (95% CI 2-5) for amoxicillin, and 4% (95% CI 2-5) for tetracycline.

87 Clarithromycin, amoxicillin, and a pump proton inhibitor are the most co

88 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin).

89 s with reduced susceptibility to ampicillin, amoxicillin, and cefotaxime, antibiotics commonly used t

90 The efficacy of oral doxycycline, amoxicillin, and cefuroxime axetil for treating Lyme dis

91 of 3 treatment groups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple therapy); 5-day

92 consisting of a proton pump inhibitor (PPI), amoxicillin, and clarithromycin.

93 rgical site for a longer period of time than amoxicillin, and patients taking azithromycin exhibited

94 specific IgE to penicillin G, penicillin V, amoxicillin, and piperacillin, using histone H1 as a car

95 at induce resistance patterns to cefotaxime, amoxicillin, and tetracycline, highlighting MDR P. aerug

96 Among amoxicillin- and clavulanate-associated cases of Europea

97 ecause severe anaphylactic reactions to oral amoxicillin are rare.

98 infants (2.8%) had treatment failure in the amoxicillin arm and 25 (5.9%) in the placebo arm (risk d

99 fants fulfilled per protocol criteria in the amoxicillin arm and 426 in the placebo arm.

100 arm died, whereas no deaths occurred in the amoxicillin arm.

101 lowing prescription of clarithromycin versus amoxicillin at 0-14 days, 15-30 days, and 30 days to 1 y

102 s were tested in vitro for susceptibility to amoxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycyclin

103 sed risk of CV hospitalization compared with amoxicillin at both 0-14 days (HR 1.31; 95% CI 1.17-1.46

104 up to assess reactions to subsequent use of amoxicillin at the time of illness in cases with negativ

105 A label-free biosensing strategy for amoxicillin (AX) allergy diagnosis based on the combinat

106 vel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate.

107 ivity reactions to clavulanic acid (CLV) and amoxicillin (AX), probably due to their increased prescr

108 Amoxicillin (AX), which is often prescribed alongside cl

109 c gradient strip susceptibility testing with amoxicillin, azithromycin, clindamycin, ciprofloxacin, a

110 ulting from a single dose of azithromycin or amoxicillin before surgical placement of one-stage denta

111 and/or pbp3 within coding regions near known amoxicillin binding motifs.

112 high level of safety associated with use of amoxicillin by dentists and the significantly worse rate

113 easing the susceptibility of the organism to amoxicillin, by repurposing the beta-lactamase inhibitor

114 amoxicillin index, defined as the number of amoxicillin CAF standard units divided by the total numb

115 In the amoxicillin, cefdinir, and placebo groups, 88.7%, 90.9%,

116 e, with severe acute malnutrition to receive amoxicillin, cefdinir, or placebo for 7 days in addition

117 The isolates had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linez

118 ins exhibited multi-drug resistance (MDR) to amoxicillin, cefotaxime, tetracycline, and gentamicin.

119 of MA-ARB under different concentrations of amoxicillin, cephalexin, tetracycline, florfenicol and v

120 Direct amoxicillin challenge is appropriate for patients with l

121 llin skin testing (PST) with or without oral amoxicillin challenge was the main intervention describe

122 s 95% and approaches 100% when combined with amoxicillin challenge.

123 compounds were stable during cooking except amoxicillin, chlortetracycline and tylosin (reductions >

124 hereof, 373 received treatment consisting of amoxicillin, clarithromycin and PPI (AC/PPI).

125 idazole (sequential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomit

126 In contrast, amoxicillin clavulanate and troglitazone did not interfe

127 The most commonly implicated drugs were amoxicillin-clavulanate (21 of 96; 22%), diclofenac (6%)

128 Either intravenous amoxicillin-clavulanate (at doses of 1 g and 200 mg, res

129 Receipt of amoxicillin-clavulanate (HR, 6.48; 95% CI, 1.43-29.4; P

130 1/145 isolates tested that were resistant to amoxicillin-clavulanate (resistance breakpoint >/= 16/8

131 beta-Lactam agents (amoxicillin-clavulanate and cefpodoxime-proxetil) are no

132 sceptible to ciprofloxacin, chloramphinicol, amoxicillin-clavulanate and ceftriaxone.

133 5:02, allo-purinol and HLA-B*58:01, and both amoxicillin-clavulanate and nevirapine with multiple cla

134 ulence, and resistance of M. tuberculosis to amoxicillin-clavulanate and vancomycin.

135 Overall 35,252 patients received amoxicillin-clavulanate as outpatients, and DILI occurre

136 oxifloxacin, levofloxacin, ciprofloxacin, or amoxicillin-clavulanate at outpatient visits.

137 s of age, with acute otitis media to receive amoxicillin-clavulanate either for a standard duration o

138 Children who were treated with amoxicillin-clavulanate for 5 days were more likely than

139 A 2-day course of antibiotic therapy with amoxicillin-clavulanate in patients receiving a 32-to-34

140 omly allocated to receive either 40 mg/kg of amoxicillin-clavulanate or a placebo mixture per day for

141 to DILI in patients treated with fasiglifam, amoxicillin-clavulanate or flucloxacillin and in primary

142 acin-colistin eardrops (76 children) or oral amoxicillin-clavulanate suspension (77) or to undergo in

143 Compared with amoxicillin-clavulanate treatment, the use of azithromyc

144 Amoxicillin-clavulanate was the most commonly implicated

145 ed prescribing data on 3 common antibiotics (amoxicillin-clavulanate, amoxicillin, and azithromycin).

146 scribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides.

147 illin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate.

148 flucloxacillin, ximelagatran, lapatinib, and amoxicillin-clavulanate.

149 The implicated agents included amoxicillin/clavulanate (n = 3), temozolomide (n = 3), v

150 An oral fluoroquinolone plus amoxicillin/clavulanate (or plus clindamycin if penicill

151 meta-analysis demonstrates that intravenous amoxicillin/clavulanate and oral amoxicillin might be th

152 ntravenous administration of 1,000/200 mg of amoxicillin/clavulanate provided the least incidence of

153 rapy associating intravenous amoxicillin and amoxicillin/clavulanate was administered.

154 Amoxicillin/clavulanate was the most frequently prescrib

155 scherichia coli cultured with amoxicillin or amoxicillin/clavulanate, a beta-lactam and beta-lactamas

156 orally administered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited mar

157 and 100% susceptible in vitro to ampicillin, amoxicillin/clavulanate, vancomycin, and teicoplanin.

158 e successfully treated with further cycle of amoxicillin/clavulanate.

159 underwent nonoperative management (NOM) with amoxicillin/clavulanate.

160 tracyclines < azithromycin < metronidazole < amoxicillin + clavulanic acid < clarithromycin < penicil

161 than the other penicillins, penicillin V and amoxicillin + clavulanic acid, and appears to be very sa

162 oli from group B showed higher resistance to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulf

163 ay in patients treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazob

164 oral ciprofloxacin (750 mg twice daily) plus amoxicillin/clavulanic acid (1,000 mg twice daily).

165 an extended-spectrum beta-lactam antibiotic amoxicillin/clavulanic acid and a first-generation cepha

166 eta-lactamase inhibitors and cephalosporins (amoxicillin/clavulanic acid MIC >= 256 mug/mL; ceftriaxo

167 AAD were found between the residents taking amoxicillin/clavulanic acid or ciprofloxacin.

168 resistance to trimethoprim-sulfamethoxazole, amoxicillin/clavulanic acid, and ciprofloxacin.

169 immediate reactions after administration of amoxicillin-CLV.

170 atched adults treated with oral amoxicillin (amoxicillin cohort = 178 179 prescriptions).

171 RD compared to 46 (0.026%) among the matched amoxicillin cohort.

172 ffect of systemic antibiotics (azithromycin, amoxicillin, cotrimoxazole, or placebo) on the gut resis

173 In secondary analyses, amoxicillin decreased the risk of transfer to inpatient

174 tom severity (1.69 with placebo vs 1.62 with amoxicillin; difference -0.07 [95% CI -0.15 to 0.007]; p

175 s were in-vitro susceptible to penicillin G, amoxicillin, doxycycline, rifampicin and gentamicin.

176 d exosomal proteins covalently modified with amoxicillin, flucloxacillin, and nitroso-sulfamethoxazol

177 cin (triple therapy); 5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromyc

178 Malawi, to determine whether treatment with amoxicillin for 3 days is less effective than treatment

179 lpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days (group C); or injectable gentamic

180 rence group); injectable gentamicin and oral amoxicillin for 7 days (group B); injectable procaine be

181 or injectable gentamicin for 2 days and oral amoxicillin for 7 days (group D).

182 pothesis that ambulatory treatment with oral amoxicillin for 7 days was equivalent (similarity margin

183 e aimed to compare the benefits and harms of amoxicillin for acute lower-respiratory-tract infection

184 uninfected Malawian children, treatment with amoxicillin for chest-indrawing pneumonia for 3 days was

185 rica guidelines that recommend ampicillin or amoxicillin for children hospitalized with community-acq

186 ld Health Organization (WHO) recommends oral amoxicillin for patients who have pneumonia with tachypn

187 d Health Organization recommendation of oral amoxicillin for the treatment of fast-breathing pneumoni

188 d with other penicillins and alternatives to amoxicillin for those who are penicillin allergic.

189 When used to quantify amoxicillin, good distinction is achieved between soluti

190 ecovery occurred in 65.9% of children in the amoxicillin group (790 of 1199) and in 62.7% of children

191 compared with 221 (19%) infants in the oral amoxicillin group (risk difference -2.6%, 95% CI -6.0 to

192 1038 patients were assigned to the amoxicillin group and 1023 to the placebo group.

193 interleukin (IL)-6 and IL-8 in GCF than the amoxicillin group and exhibited significantly lower leve

194 patients in the placebo group and one in the amoxicillin group needed to be admitted to hospital; no

195 mptoms were significantly less common in the amoxicillin group than in the placebo group (162 [15.9%]

196 rrhoea were significantly more common in the amoxicillin group than in the placebo group (number need

197 nsfer to inpatient care by 14% (26.4% in the amoxicillin group vs. 30.7% in the placebo group; risk r

198 n (1999 in the placebo group and 2003 in the amoxicillin group).

199 was higher in the placebo group than in the amoxicillin group, a difference that did not meet the no

200 cin group and 1145 (98%) infants in the oral amoxicillin group.

201 acebo group and in 58 children (3.1%) in the amoxicillin group.

202 Oral 3 g of amoxicillin had the least incidence of postdental proced

203 l containing cluster for both ampicillin and amoxicillin has a clear tendency to rise with sample kee

204 , revealing the therapeutic potential of the amoxicillin-imipenem-relebactam combination.

205 A shorter course of amoxicillin improves adherence to therapy, is low in cos

206 mycin sensitivity was present in 30(64%) and amoxicillin in 45(98%), respectively.

207 of how Mtb responds to beta-lactams such as Amoxicillin in combination with Clav (referred as Augmen

208 , amoxicillin (15 mug/mL), metronidazole and amoxicillin in combination, doxycycline (2 mug/mL), and

209 udy of patients prescribed clarithromycin or amoxicillin in the community in Tayside, Scotland (popul

210 ial failed to show equivalence of placebo to amoxicillin in the management of isolated fast breathing

211 Phenotypic resistance to amoxicillin in three isolates correlated with mutations

212 Prescribing of ampicillin/amoxicillin increased following guideline publication, b

213 The amoxicillin index was low (median 30.7%, IQR 14.3-47.3).

214 d by the total number of CAF standard units; amoxicillin index, defined as the number of amoxicillin

215 th a high incidence of DILI (flucloxacillin, amoxicillin, isoniazid, and nitroso-sulfamethoxazole) to

216 T and levofloxacin-containing therapy (PPI + amoxicillin + levofloxacin).

217 cs most commonly prescribed were as follows: amoxicillin < cephalosporins < erythromycin < tetracycli

218 44,618 discrete prescribing episodes [37,497 amoxicillin, mean age 63 years, 56% male; 7,121 clarithr

219 omycin, mean age 73 years, 42% male; 171,153 amoxicillin, mean age 74 years, 45% male).

220 he clinical and microbiological responses of amoxicillin + metronidazole (AMX + MET) versus clarithro

221 ruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and

222 6-2000-fold lower than the five antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, a

223 ans, were resistant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3

224 pplemented with increasing concentrations of amoxicillin, metronidazole, or their combination and inc

225 mes of periodontal therapy supplemented with amoxicillin-metronidazole during either the non-surgical

226 intravenous amoxicillin/clavulanate and oral amoxicillin might be the best prophylactic interventions

227 he enzyme activity through the estimation of amoxicillin minimum inhibitory concentration on a subset

228 An amoxicillin-modified 9-mer peptide derived from the exos

229 ere allocated randomly to receive either 2 g amoxicillin (n = 7) or 500 mg azithromycin (n = 6) befor

230 and in recognition and treatment (with oral amoxicillin) of suspected neonatal respiratory infection

231 g alone can be effectively treated with oral amoxicillin on an outpatient basis when referral to a ho

232 ct of routinely used higher dose regimens of amoxicillin on gram-negative bacteria and antibiotic res

233 nt strains of Escherichia coli cultured with amoxicillin or amoxicillin/clavulanate, a beta-lactam an

234 These results suggest that exposure to amoxicillin or ampicillin/neomycin can alter the biodisp

235 aged 2-59 months were randomized to receive amoxicillin or benzyl penicillin and followed up for the

236 cantly lower for samples treated with either amoxicillin or metronidazole compared with controls (P <

237 riple therapy (PPI + clarithromycin + either amoxicillin or metronidazole) is restricted to areas wit

238 stant to the Malawian first-line antibiotics amoxicillin or penicillin, chloramphenicol, and co-trimo

239 licated severe acute malnutrition to receive amoxicillin or placebo for 7 days.

240 ere randomly assigned to receive either oral amoxicillin or placebo twice daily for 7 days.

241 treatment failure during the 3-day course of amoxicillin or placebo.

242 reatment with the antibiotics ciprofloxacin, amoxicillin, or a cocktail of ampicillin/neomycin.

243 enicillin, ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate.

244 tructurally related beta-lactam antibiotics (amoxicillin, oxacillin, penicillin G).

245 y associated with allergy to penicillins and amoxicillin (P = 6.0 x 10(-4) and P = 4.0 x 10(-4), resp

246 actic acid) (PDLLA) nanofibers encapsulating amoxicillin (PDLLA-AMX) were fabricated using the electr

247 oup (n = 12), which received FMUD and 375 mg amoxicillin plus 250 mg metronidazole for 7 days.

248 riodontal treatment supplemented with 375 mg amoxicillin plus 500 mg metronidazole, three times daily

249 culous cholecystitis and who received 2 g of amoxicillin plus clavulanic acid 3 times a day while in

250 iotics, lack of postoperative treatment with amoxicillin plus clavulanic acid did not result in a gre

251 Amoxicillin plus metronidazole did not significantly aff

252 nced periodontitis benefit specifically from amoxicillin plus metronidazole given as an adjunct to fu

253 It has been suggested that prescription of amoxicillin plus metronidazole in the context of periodo

254 mycetemcomitans had no specific benefit from amoxicillin plus metronidazole.

255 treatment associated with metronidazole and amoxicillin promoted a beneficial change in the microbio

256 ng rifabutin-based triple and high-dose dual amoxicillin proton pump inhibitor therapy for subsequent

257 When pneumonia is not suspected clinically, amoxicillin provides little benefit for acute lower-resp

258 ipients (95 of 1927 children) and 2.6% among amoxicillin recipients (51 of 1929 children) (between-gr

259 s suggest that a single prophylactic dose of amoxicillin reduces early implant complications, but it

260 Exceptionally high amoxicillin resistance was observed among Gram positive

261 harmaceutical ingredients (APIs) ampicillin, amoxicillin, rifampicin, isoniazid, ethambutol, and pyra

262 h procaine benzylpenicillin, gentamicin, and amoxicillin (risk difference with reference 1.1, -2.3 to

263 Amoxicillin shows two peaks at 0.909 cm(2)/(V s) and 0.9

264 However, amoxicillin still continues to be used customarily in se

265 t-breathing pneumonia were treated with oral amoxicillin suspension (50 mg/kg/day) for 3 days in 14 i

266 er define mutations conferring resistance to amoxicillin, tetracycline, and rifampin, but combinatori

267 ssigned to a 3-day course of a suspension of amoxicillin (the active control) of 50 mg per milliliter

268 Ampicillin/amoxicillin therapy started within the past 30 days was

269 ntibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per day for 7 days) during the f

270 from studies showing noninferiority of oral amoxicillin to benzyl penicillin for severe pneumonia ma

271 Our findings confirm noninferiority of amoxicillin to benzyl penicillin, provide estimates of r

272 anic acid, which is used in combination with amoxicillin to overcome beta-lactamase-mediated antibiot

273 pnea, yet trial data indicate that not using amoxicillin to treat this condition may be noninferior t

274 dren presenting with a rash in the course of amoxicillin treatment are currently unknown.

275 We aimed to assess whether oral amoxicillin treatment for fast breathing, in the absence

276 ylpenicillin-gentamicin once per day or oral amoxicillin treatment twice per day for 7 days.

277 icin once a day for 7 days (reference); oral amoxicillin twice daily and intramuscular gentamicin onc

278 micin once a day for 2 days followed by oral amoxicillin twice daily for 5 days.

279 pneumonia were randomly assigned to receive amoxicillin twice daily for either 3 days or 5 days.

280 entamicin once per day for 2 days, then oral amoxicillin twice per day for 5 days (group C).

281 tramuscular gentamicin once per day and oral amoxicillin twice per day for 7 days (group B) or intram

282 ven hybrid therapy (40 mg omeprazole and 1 g amoxicillin, twice daily for 14 days; 500 mg clarithromy

283 treated with 40 mg pantoprazole and 1000 mg amoxicillin, twice daily for the first 5 days, followed

284 vestigate the association between ampicillin/amoxicillin use and KPLA in Taiwan.

285 d rising to 13.5% and 16.8% by day 14 in the amoxicillin vs benzyl penicillin groups, respectively.

286 hood of nutritional recovery (risk ratio for amoxicillin vs. placebo, 1.05; 95% confidence interval [

287 CV events with clarithromycin compared with amoxicillin was associated with an interaction with P-gl

288 2.77 +/- 0.90 mug/mL, respectively, whereas amoxicillin was below the limit of detection.

289 Only DAP (10 mg/kg) plus AMP or amoxicillin was efficacious against a DAP-R E. faecium s

290 concentration at 90% [MIC90] 0.25 mg/L), and amoxicillin was most active against S. intermedius (MIC9

291 Indeed, amoxicillin was respectively 6 and 3 times less likely t

292 recent and past FQ users when compared with amoxicillin were 1.47 (95% CI: 1.03 to 2.09) and 1.06 (9

293 ory concentrations (MICs) for ampicillin and amoxicillin were 8-fold higher, and the MIC for cefotaxi

294 ory concentrations (MICs) for ampicillin and amoxicillin were 8-fold higher, and the MIC for cefotaxi

295 children referred with suspected allergy to amoxicillin were approached.

296 nation of Amoxicillin and Metronidazole, and Amoxicillin were the three most commonly prescribed syst

297 etronidazole, while significantly worse than amoxicillin, were 3 and nearly 5 times less likely to ca

298 tolerance to subsequent full treatment with amoxicillin, while 6 (10.9%) developed nonimmediate cuta

299 The MICs of amoxicillin with clavulanate, ampicillin, chloramphenico

300 djusted OR associating the use of ampicillin/amoxicillin within the past 30 days with KPLA was 3.5 (9